Plasma glucose low enough to cause neuroglycopenic or autonomic symptoms; medical emergency if severe.
Also known as: hypoglycemia, low blood sugar, insulin reaction, neuroglycopenia
Overview
Plasma glucose level sufficiently low to produce symptoms or impair physiologic function. ADA Level 1: glucose <70 mg/dL (alert value); Level 2: <54 mg/dL (clinically significant); Level 3: severe event requiring external assistance for recovery regardless of glucose value.
Epidemiology
Most common acute complication of insulin therapy. In T1DM, average ~2 symptomatic episodes per week and 1 severe event per year. Severe hypoglycemia affects ~25% of insulin-treated T2DM patients annually. Increases mortality and is associated with cognitive decline.
Try two board-style Hypoglycemia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1EndocrineMedium
A 58-year-old male with type 2 diabetes on metformin and glipizide presents with sweating, tremor, and confusion at 11 AM. He reports skipping breakfast. Glucose is 42 mg/dL. After D50 administration he improves. Which of the following is the most likely mechanism of this episode?
AMetformin reducing hepatic glucose production
BCortisol deficiency impairing gluconeogenesis
CGlipizide-induced insulin secretion
DAutonomous insulin secretion from an insulinoma
Reveal answer & full explanation
Correct answer: C — Glipizide-induced insulin secretion
AMetformin reducing hepatic glucose production
BCortisol deficiency impairing gluconeogenesis
CGlipizide-induced insulin secretion✓
DAutonomous insulin secretion from an insulinoma
Why Glipizide-induced insulin secretion is correct
Sulfonylureas (glipizide, glyburide) close ATP-sensitive K+ channels in pancreatic beta cells, depolarizing the membrane and triggering insulin release
This insulin release is independent of the ambient glucose level, so it continues even when the patient skips a meal and glucose falls
Sulfonylureas are the leading oral hypoglycemic class to cause hypoglycemia, especially with missed meals, renal impairment, or advanced age
The classic setting is an elderly diabetic on a sulfonylurea who skips a meal, exactly as seen here
Why the others are wrong
Metformin reducing hepatic glucose production — right-drug-wrong-mechanism: metformin lowers hepatic gluconeogenesis and improves insulin sensitivity in a glucose-dependent manner and does not cause hypoglycemia as monotherapy
Cortisol deficiency impairing gluconeogenesis — confused-with adrenal insufficiency: cortisol deficiency can cause hypoglycemia but would present with hypotension, hyponatremia, and hyperkalemia rather than isolated meal-timed hypoglycemia in a patient on a sulfonylurea
Autonomous insulin secretion from an insulinoma — right-concept-wrong-setting: insulinoma is considered in a nondiabetic with the Whipple triad, not in a diabetic whose hypoglycemia is fully explained by a sulfonylurea and a missed meal
Additional high-yield points
Sulfonylurea-induced hypoglycemia can be prolonged and recurrent; these patients often require admission and a dextrose infusion rather than a single D50 push
Octreotide is an antidote for refractory sulfonylurea hypoglycemia because it suppresses further insulin release
Insulinoma is diagnosed with a 72-hour fast showing hypoglycemia with inappropriately elevated insulin, C-peptide, and proinsulin; a sulfonylurea screen must be sent to exclude surreptitious drug use
Question 2EndocrineEasy
A 29-year-old man with type 1 diabetes is confused and diaphoretic after taking rapid-acting insulin but skipping breakfast. Fingerstick glucose is 42 mg/dL, and he can safely swallow. Which of the following is the most appropriate initial treatment?
AIntramuscular glucagon rescue dose
BOral fast-acting carbohydrate intake
CSubcutaneous long-acting insulin dose
DReassurance with repeat glucose later
Reveal answer & full explanation
Correct answer: B — Oral fast-acting carbohydrate intake
AIntramuscular glucagon rescue dose
BOral fast-acting carbohydrate intake✓
CSubcutaneous long-acting insulin dose
DReassurance with repeat glucose later
Why Oral fast-acting carbohydrate intake is correct
A conscious patient with a glucose of 42 mg/dL who can protect his airway should be treated by the least invasive effective route: 15-20 g of oral fast-acting carbohydrate, then recheck.
Skipping a meal after rapid-acting insulin is the classic insulin-meal mismatch that produced the hypoglycemia.
Confusion is the neuroglycopenic clue and diaphoresis the adrenergic one, but oral glucose corrects both quickly when swallowing is safe.
Why the others are wrong
Subcutaneous long-acting insulin dose — Giving more insulin during hypoglycemia is the wrong-direction trap and would deepen the low glucose.
Intramuscular glucagon rescue dose — Glucagon is reserved for the patient who cannot safely swallow; using it when oral intake is feasible is the right-drug-wrong-patient trap and risks vomiting/aspiration.
Reassurance with repeat glucose later — Watchful waiting at 42 mg/dL with neuroglycopenia is the dangerous under-treatment trap; symptomatic hypoglycemia must be treated now.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Hypoglycemia outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Insulinoma, factitious (surreptitious insulin or sulfonylurea use)
Pathophysiology
Glucose is the obligate fuel of the CNS. When plasma glucose falls below ~70 mg/dL, insulin secretion suppresses, then glucagon and epinephrine rise (autonomic symptoms). Below ~54 mg/dL, cortisol and growth hormone respond, and neuroglycopenia develops. Repeated hypoglycemia blunts the counter-regulatory response, producing hypoglycemia unawareness.
Reactive (postprandial) hypoglycemia — Symptoms 2-4 h post-meal, especially after gastric bypass; OGTT or mixed-meal tolerance test reproduces; insulin/C-peptide appropriately suppressed
Non-islet cell tumor hypoglycemia — Large mesenchymal tumors producing big IGF-2; low insulin, low C-peptide, elevated IGF-2:IGF-1 ratio
Alcohol-induced — Heavy intake without food; impaired gluconeogenesis; treat with glucose + thiamine
Seizure, stroke, syncope (mimics) — Neurologic events without low glucose; check fingerstick in any acute neurologic presentation
POC fingerstick glucose — confirm low value before treating in non-emergent setting
Serum glucose to confirm
If etiology unclear, draw a 'critical sample' at the time of hypoglycemia: insulin, C-peptide, proinsulin, beta-hydroxybutyrate, sulfonylurea screen, cortisol, growth hormone
BMP, LFTs, TSH (rule out adrenal, hepatic, hypothyroid contribution)
Consider 72-hour supervised fast for insulinoma workup if no other cause identified
Imaging
Not needed for acute event
CT, MRI, or endoscopic ultrasound for insulinoma localization once biochemical diagnosis confirmed
Selective arterial calcium stimulation testing if imaging negative
Diagnostic algorithm
Etiology
Insulin
C-peptide
Proinsulin
β-OHB
Sulfonylurea screen
Insulinoma
High
High
High
Low
Negative
Sulfonylurea (oral hypoglycemic)
High
High
Normal/high
Low
Positive
Exogenous insulin (factitious)
High
LOW (suppressed)
Low
Low
Negative
Non-islet cell tumor (IGF-2)
Low
Low
Low
Low
Negative
Adrenal insufficiency
Low
Low
Low
Elevated
Negative
Alcohol / starvation
Low
Low
Low
Elevated
Negative
Hypoglycemia workup — critical sample interpretation (drawn AT the time of documented low glucose).
Complications
Seizure, coma, anoxic brain injury, death (especially nocturnal episodes)
Anxiety, fear of hypoglycemia leading to deliberate hyperglycemia
PANCE pearls
Whipple triad confirms true hypoglycemia — don't chase asymptomatic 'low' readings on CGM or fingerstick in non-diabetics.
Critical sample drawn at the time of low glucose is the highest-yield test for diagnostic workup — once glucose normalizes, hormone levels lose interpretability.
Glyburide is long-acting and renally cleared — admit ALL elderly or CKD patients with glyburide-induced hypoglycemia for at least 24 hours.
Octreotide suppresses sulfonylurea-induced insulin release and is the antidote of choice for refractory sulfonylurea hypoglycemia.
Recurrent fasting hypoglycemia in a non-diabetic is insulinoma until proven otherwise.
References
ADA 2025 — American Diabetes Association Standards of Care in Diabetes—2025: Glycemic Goals and Hypoglycemia (Diabetes Care 2025; 48 Suppl 1)
Endocrine Society 2009 — Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (Cryer et al., J Clin Endocrinol Metab 2009)
ADA/EASD 2017 — International Hypoglycaemia Study Group: Glucose Concentrations of Less than 3.0 mmol/L Should Be Reported in Clinical Trials
Practice Endocrinology questions on FirstPassPA
Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.